Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
LIPO 
Lipella Pharmaceuticals Inc. Common Stock (LIPO)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
09/11/2025: LIPO (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
1 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $10
1 Year Target Price $10
| 0 | Strong Buy |
| 1 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -29.91% | Avg. Invested days 10 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 09/11/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 2.73M USD | Price to earnings Ratio - | 1Y Target Price 10 |
Price to earnings Ratio - | 1Y Target Price 10 | ||
Volume (30-day avg) 1 | Beta -0.09 | 52 Weeks Range 0.55 - 4.69 | Updated Date 09/12/2025 |
52 Weeks Range 0.55 - 4.69 | Updated Date 09/12/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -3.33 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Earnings Date
Report Date 2025-09-03 | When - | Estimate - | Actual -0.31 |
Profitability
Profit Margin - | Operating Margin (TTM) -1564.19% |
Management Effectiveness
Return on Assets (TTM) -118.45% | Return on Equity (TTM) -248.36% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 265229 | Price to Sales(TTM) 5.8 |
Enterprise Value 265229 | Price to Sales(TTM) 5.8 | ||
Enterprise Value to Revenue 0.49 | Enterprise Value to EBITDA -4.4 | Shares Outstanding 4620840 | Shares Floating 4329355 |
Shares Outstanding 4620840 | Shares Floating 4329355 | ||
Percent Insiders 6.53 | Percent Institutions 1.35 |
Upturn AI SWOT
Lipella Pharmaceuticals Inc. Common Stock
Company Overview
History and Background
Lipella Pharmaceuticals Inc. is a biopharmaceutical company focused on developing new therapies for patients with serious diseases with significant unmet medical needs. It was founded to develop therapies for bladder diseases.
Core Business Areas
- Pharmaceutical Development: Focuses on the research, development, and commercialization of pharmaceutical products, particularly for bladder diseases.
Leadership and Structure
The company is led by a management team with experience in pharmaceutical development and commercialization. Details of the exact organizational structure and current management should be confirmed via their official website or regulatory filings.
Top Products and Market Share
Key Offerings
- LP-10: Lipella's lead product candidate, LP-10, is being developed for hemorrhagic cystitis. There is no specific revenue or market share data publicly available for this product. Competitors depend on what type of cystitis treatment they are treating.
Market Dynamics
Industry Overview
The pharmaceutical industry is highly competitive and heavily regulated. It involves research, development, manufacturing, and marketing of drugs and therapies. The Cystitis treatment market is evolving.
Positioning
Lipella focuses on niche markets with unmet medical needs, specifically bladder diseases. Their competitive advantage would depend on their success in clinical trials and regulatory approvals.
Total Addressable Market (TAM)
TAM for hemorrhagic cystitis is substantial given the relatively small number of approved treatments. Lipella's position depends on the clinical efficacy and market penetration of LP-10.
Upturn SWOT Analysis
Strengths
- Focus on unmet medical needs
- Proprietary drug development pipeline
- Experienced management team
Weaknesses
- Limited financial resources
- Dependence on clinical trial outcomes
- Lack of commercialized products
Opportunities
- Positive clinical trial results
- Regulatory approval for LP-10
- Strategic partnerships with larger pharmaceutical companies
Threats
- Clinical trial failures
- Regulatory hurdles
- Competition from established pharmaceutical companies
Competitors and Market Share
Key Competitors
- JAZZ (JAZZ)
- EIGR (EIGR)
- AVEO (AVEO)
Competitive Landscape
Lipella faces competition from established pharmaceutical companies with greater resources and experience. Its success depends on its ability to develop and commercialize innovative therapies. Market share data is estimated and may not be exact.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is limited due to its development stage.
Future Projections: Future growth depends on successful clinical trials, regulatory approvals, and commercialization of LP-10.
Recent Initiatives: Recent initiatives likely include clinical trial progress, regulatory submissions, and fundraising activities. Needs to be validated with recent news.
Summary
Lipella Pharmaceuticals is a development-stage biopharmaceutical company focused on unmet medical needs, particularly bladder diseases. Its future success hinges on the clinical trial outcomes and regulatory approvals of LP-10. Limited financial resources and competition from larger companies present challenges. Positive clinical results and strategic partnerships could significantly improve its outlook. The company needs to effectively manage its finances and successfully navigate the regulatory landscape.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- Third-party financial data providers
Disclaimers:
The data and analysis provided are for informational purposes only and should not be considered financial advice. Investment decisions should be based on thorough research and consultation with a financial advisor. Market share data is estimated.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Lipella Pharmaceuticals Inc. Common Stock
Exchange NASDAQ | Headquaters Pittsburgh, PA, United States | ||
IPO Launch date 2022-12-19 | Co-Founder, Chairman, CEO, President, Secretary & Treasurer Dr. Jonathan Kaufman M.B.A., Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 5 | Website https://lipella.com |
Full time employees 5 | Website https://lipella.com | ||
Lipella Pharmaceuticals Inc., a clinical-stage biotechnology company, focuses on developing drugs by reformulating the active agents in existing generic drugs and optimizing these reformulations for various applications. It develops LP-10, a formulation of tacrolimus for patients with radiation-induced hemorrhagic cystitis; LP-310, a formulation of tacrolimus for the treatment of oral lichen planus; LP-410, an oral liposomal formulation of tacrolimus to treat oral graft-versus-host disease; and LP-50, an intravesical formulation of immunoglobulins for the treatment of non-muscle invasive bladder cancer. Lipella Pharmaceuticals Inc. was incorporated in 2005 and is headquartered in Pittsburgh, Pennsylvania.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.